StoxSyngene International vs Concord Biotech: share price & financials comparison
NSE: SYNGENE vs CONCORDBIO · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Syngene International vs Concord Biotech at a glance
Syngene International (SYNGENE) has a market capitalisation of ₹17,936 Cr, against ₹6,214 Cr for Concord Biotech (CONCORDBIO). Over the past year Concord Biotech has returned -18.3%, compared with -31.3% for Syngene International. On valuation, Concord Biotech trades at a lower P/E of 22.0 versus 469.5. Concord Biotech earns a higher return on equity (13.6% vs 0.8%). Syngene International comes out ahead on technicals. Concord Biotech comes out ahead on size, valuation, profitability and momentum. Across the scored metrics below, Syngene International leads on 3 and Concord Biotech on 11. On StoxGud's 10-point checklist, Syngene International scores 3/10 and Concord Biotech scores 6/10.
| Metric | Syngene International | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹17,936 Cr | ₹6,214 Cr |
| Revenue (latest FY) | ₹3,739 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 469.5 | 22.0 |
| P/B | 3.69 | 2.99 |
| Dividend yield | 0.28% | 1.80% |
| Profitability | ||
| Return on equity | 0.8% | 13.6% |
| Net profit margin | 1.1% | 24.1% |
| Operating margin | 21.3% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | -8.6% | +25.1% |
| Net profit growth (YoY) | — | +11.1% |
| Revenue CAGR (multi-year) | +11.3% | +1.8% |
| Financial health | ||
| Debt to equity | 0.01 | 0.00 |
| Momentum | ||
| 1-month return | +17.1% | -13.3% |
| 1-year return | -31.3% | -18.3% |
| 3-year CAGR | -14.4% | -3.0% |
| 5-year CAGR | -5.6% | — |
| 10-year CAGR | +5.1% | — |
| Distance from 52W high | -33.1% | -25.2% |
| Technicals | ||
| RSI (14) | 77 | 47 |
| Price vs 200-day avg | +5.4% | -6.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Syngene International | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 3/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Syngene International or Concord Biotech?
Syngene International has a market cap of ₹17,936 Cr and Concord Biotech has a market cap of ₹6,214 Cr as of 13 Nov 2026.
Which has a lower P/E, Syngene International or Concord Biotech?
Concord Biotech has the lower P/E: Syngene International trades at 469.5 and Concord Biotech at 22.0.
Which gave better returns in the last year, Syngene International or Concord Biotech?
Concord Biotech did better: Syngene International returned -31.3% and Concord Biotech returned -18.3% over one year.
What is the difference between Syngene International and Concord Biotech?
Both are NSE-listed companies in Healthcare. Syngene International is about 2.9 times the size of Concord Biotech by market cap. In the latest financial year Syngene International reported revenue of ₹3,739 Cr and Concord Biotech ₹1,055 Cr. Operating margin is 21.3% for Syngene International and 34.5% for Concord Biotech. Debt to equity is 0.01 for Syngene International and 0.00 for Concord Biotech.
Which is better, Syngene International or Concord Biotech?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Syngene International leads on 3 and Concord Biotech on 11. Syngene International is ahead on technicals. Concord Biotech is ahead on size, valuation, profitability and momentum. On StoxGud's rules-based checklist Syngene International scores 3/10 and Concord Biotech scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.